Global Point of Care
Global Point of Care
Dengue and Hepatitis are two of the most important diseases in the country, both at the local and national government level. In the Devolution Transition Plan issued by Department of Health (DOH), these two programs are now devolved to Local Government Units (LGUs).1
The first recorded dengue epidemic in Southeast Asia occurred in Manila in 1954, and dengue has since remained endemic.2 In the latest report, there was an observed 30% increase in the number of dengue cases after the start of the rainy season. There were also seven regions that remain on high alert due to the spike in the six weeks before June 29: National Capital Region (NCR), CALABARZON, MIMAROPA, Cagayan Valley, Western Visayas, Ilocos Region and Central Luzon.3
Rapid testing is critical for early diagnosis of dengue infection. While dengue fever may be diagnosed clinically, use of rapid test helps secure a definitive diagnosis.4
Explore our diagnostic tools for rapid results and comprehensive detection in the fight against dengue.
Around one in 10 people have chronic hepatitis B, and six in 1,000 have chronic hepatitis C. To eliminate this deadly disease, we must invest in hepatitis testing and treatment services.
Aside from a program like the Devolution Transition Plan being the right thing to do for people’s health, it is also a very wise investment, as it can save money by avoiding much more costly care for liver cancer and cirrhosis.5
Learn how our solutions can help in the early identification and effective management of hepatitis B and C, contributing to global efforts to eliminate these diseases.
A Leader in Rapid Point-of-Care Diagnostics.
©2025 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.
Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. GDPR Statement.
Not all products are available in all regions. Check with your local representative for availability in specific markets. For in vitro diagnostic use only. For i-STAT test cartridge information and intended use, refer to individual product pages or the cartridge information (CTI/IFU) in the i-STAT Support area.
Abbott - A Leader in Rapid Point-of-Care Diagnostics.